252 related articles for article (PubMed ID: 28209745)
1. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Sclafani F; Morano F; Cunningham D; Baratelli C; Kalaitzaki E; Watkins D; Starling N; Chau I; Rao S
Oncologist; 2017 Apr; 22(4):402-408. PubMed ID: 28209745
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor inhibition in metastatic anal cancer.
Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
6. Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study.
Truelsen CG; Serup-Hansen E; Storm KS; Havelund BM; Kronborg CS; Spindler KG
Cancer Med; 2021 May; 10(10):3224-3230. PubMed ID: 33960701
[TBL] [Abstract][Full Text] [Related]
7. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Khawandanah M; Baxley A; Pant S
J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin and paclitaxel treatment is effective in advanced anal cancer.
Kim R; Byer J; Fulp WJ; Mahipal A; Dinwoodie W; Shibata D
Oncology; 2014; 87(2):125-32. PubMed ID: 25012155
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
10. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
[TBL] [Abstract][Full Text] [Related]
12. Optimal first-line treatment for advanced thymic carcinoma.
Yang X; Zhuo M; Shi A; Yang S; Wang Z; Wu M; An T; Wang Y; Li J; Zhong J; Chen H; Jia B; Dong Z; Zhao J
Thorac Cancer; 2019 Nov; 10(11):2081-2087. PubMed ID: 31574576
[TBL] [Abstract][Full Text] [Related]
13. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA
Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Zhang XT; Li J; Bai Y; Chu YP; Li J; Li Y; Gong JF; Shen L
J Cancer Res Ther; 2013 Nov; 9 Suppl():S153-7. PubMed ID: 24516052
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.
Gao G; Chu H; Zhao L; Gui T; Xu Q; Shi J
Lung Cancer; 2012 Jun; 76(3):380-6. PubMed ID: 22226626
[TBL] [Abstract][Full Text] [Related]
18. Systemic Therapies for Advanced Squamous Cell Anal Cancer.
Sclafani F; Rao S
Curr Oncol Rep; 2018 May; 20(7):53. PubMed ID: 29728940
[TBL] [Abstract][Full Text] [Related]
19. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
20. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]